Regenerative medicine

Development of new periodontal tissue regeneration therapy using autologous adipose tissue-derived stem cells

Principal Investigator

Graduate School of Dentistry, Osaka University


Professor Shinya MURAKAMI

Project Outline

This project aims to develop a new periodontal tissue regeneration therapy using mesenchymal stem cells separated from abdominal subcutaneous adipose tissues (ADMPC).



Periodontal disease: About 80% of adults are affected.



Periodontal disease is disease in which periodontal tissues that support teeth are destroyed because of the body of bacteria attached at the boundary between teeth and gums (dental plaque) and is the number one cause of loss of teeth, affecting about 80% of adults. Unfortunately, the lost periodontal tissues cannot be regenerated simply by removing the cause.

Clinical study Case A Case B Baseline 9M Takedachi M et al. Sci Rep. 2022

We are trying to develop a treatment method to facilitate the regeneration of periodontal tissues by the autologous transplantation of ADMPC taken from abdominal subcutaneous adipose tissues Development of periodontal tissue regeneration
therapy by ADMPC transplantation

Collection of ADMPC

Abdominal subcutaneous adipose tissue/cell
Less quantitative limitation
Reduced burden on patients

Transfusion
of cells

The first trial in the world
Meeting the needs of people who say
"I want to eat with my own teeth for life"

Regeneration of
Periodontal tissues

of each patient with periodontal disease into the lost parts of the periodontal tissues.

Until now, we have clarified the safety and efficacy of this therapeutic through clinical study to establish a new periodontal tissue regeneration therapy that can be applied to severe periodontal diseases.

Target disease: Periodontal disease Patent information: Granted (registered on February 8, 2013)

The project aims to establish a patient-friendly periodontal tissue regeneration therapy that is an unprecedented method not only in Japan but also in the world by using ADMPC collected less invasively and safely from patients.

Although the market size was 80 million yen in 2012, there are many latent patients, and it is expected that the market size will be about 80 billion yen or more in 2050. We hope the therapy becomes widely used through the collaborative development with or licensing out to the business enterprise.